MRNA Earnings & Financial Statements
Moderna, Inc.
$236.50
+$10.20(+4.51%)
60
Overall
60
Value
75
Tech
47
Quality
Market Cap
$90.35B
Volume
17.28M
52W Range
$22.28 - $225.00
Target Price
$124.71
MRNA earnings and financial statements: Moderna, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
MRNA Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $1.94B | $3.24B | $6.85B | $18.88B | $17.74B |
| Cost of revenue | $868.00M | $1.46B | $4.69B | $5.42B | $2.62B |
| Operating income | -$3.07B | -$3.94B | -$4.24B | $9.42B | $13.30B |
| EBITDA | -$2.55B | -$3.42B | -$3.32B | $9.92B | $13.54B |
| Net income | -$2.82B | -$3.56B | -$4.71B | $8.36B | $12.20B |
| EPS (diluted) | $-7.26 | $-9.28 | $-12.33 | $20.12 | $28.29 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $12.34B | $14.14B | $18.43B | $25.86B | $24.67B |
| Total liabilities | $3.69B | $3.24B | $4.57B | $6.74B | $10.52B |
| Shareholders’ equity | $8.65B | $10.90B | $13.85B | $19.12B | $14.14B |
| Cash and equivalents | $2.60B | $1.93B | $2.91B | $3.21B | $6.85B |
| Long-term debt | $1.26B | $710.00M | $1.22B | $1.00B | $705.00M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$1.87B | -$3.00B | -$3.12B | $4.98B | $13.62B |
| Capital expenditure | -$202.00M | -$1.05B | -$707.00M | -$400.00M | -$284.00M |
| Free cash flow | -$2.08B | -$4.05B | -$3.83B | $4.58B | $13.34B |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | MRNA | $236.50 | +4.5% | 17.28M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |